Summit Therapeutics plc

10/03/2019 | Press release | Distributed by Public on 10/03/2019 06:15

Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care